Sign in

CIK 0001347178

  • Accelerated filer

Vanda Pharmaceuticals Inc.

Sign in to watch
Ticker
VNDA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
030491827
Phone
+1 202-734-3400
Business address
2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON, DC, 20037
  1. 4 Grant or award SVP, Chief Marketing Officer acquired 30,000 shares (grant or award)
  2. 4 Grant or award President and CEO acquired 60,000 shares (grant or award)
  3. 4 Grant or award Chief Corp. Affairs Officer acquired 30,000 shares (grant or award)
  4. 4 Grant or award SVP, Business Development acquired 30,000 shares (grant or award)
  5. 4 Derivatives Options or other derivatives
  6. 3 Insider Initial Statement of Ownership
  7. 4 Open-market sale SVP & Chief Commercial Officer sold 1,155 shares at $16.06 ($18,551)
  8. 4 Open-market sale President and CEO sold 9,467 shares at $16.00 ($151,493)
  9. 4 Open-market sale EVP & Chief Financial Officer sold 4,020 shares at $15.94 ($64,086)
  10. 4 Open-market sale SVP, Business Development sold 4,020 shares at $15.93 ($64,021)
  11. 4 Open-market sale President and CEO sold 142,409 shares at an average $16.95 ($2,413,729)
  12. 4 Derivatives Options or other derivatives
  13. 3 Insider Initial Statement of Ownership
  14. 4 Open-market sale Director sold 15,000 shares at $14.85 ($222,750)
  15. 4 Grant or award SVP, Chief Marketing Officer acquired 30,000 shares (grant or award)
  16. 3 Insider Initial Statement of Ownership
  17. 3 Insider Initial Statement of Ownership
  18. 4 Open-market sale SVP & General Counsel sold 2,575 shares at $14.69 ($37,829)
  19. 4 Grant or award Director acquired 5,000 shares (grant or award)
  20. 4 Grant or award Director acquired 5,000 shares (grant or award)

Page 9 of 29 · 579 filings